Tempus Introduces Workspaces into its Lens Data Analytics Platform

Lens is trusted by nearly 100 institutions to uncover novel insights CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, is broadly introducing its new Workspaces feature in the Lens platform. Workspaces is a private, coding-based cloud environment designed to unblock research and accelerate innovation. This new interface provides researchers a frictionless workflow for … [Read more…]

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

New indication for this one-time infusion may provide patients with a treatment-free respite as early as first relapse SOMERSET, N.J.–(BUSINESS WIRE)–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of patients with relapsed … [Read more…]

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s ENHERTU which showed clinically meaningful responses across a broad range of tumors ENHERTU now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the … [Read more…]

Agenus Announces Reverse Stock Split of Common Stock

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced its stockholders have approved a one-for-twenty reverse stock split of its issued and outstanding common stock, which will go into effect at 12:01 a.m., Eastern Time on April 12, 2024. The reverse stock split … [Read more…]

Infectious Disease Diagnostics Research Revolution 2024: New Report Analyzes OTC and DTC Trends and Strategies Through 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “OTC/DTC Infectious Disease Diagnostics: Strategies and Trends for Over the Counter and Direct To Consumer – Forecasts by Application by Channel and by Country with Market Analysis, Executive Guides, and Market Opportunity Analysis” report has been added to ResearchAndMarkets.com’s offering. The global healthcare paradigm is shifting with the emergence of self-testing technologies and … [Read more…]

Italy Automated Microbiology Market Report 2023-2028 – Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “2023-2028 Italy Automated Microbiology Market – Growth Opportunities, 2023 Supplier Shares by Assay, Five-Year Segmentation Forecasts – Competitive Strategies and SWOT Analysis, Instrumentation Pipeline, Emerging Technologies, Market Barriers and Risks” report has been added to ResearchAndMarkets.com’s offering. This report is an analysis of the major business opportunities emerging in the automated microbiology market … [Read more…]

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) … [Read more…]

Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2023 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2024. It can be downloaded (in … [Read more…]

Quanta System on the Peaks of the Urological Laser World Once Again: Quanta Magneto Technology™

PARIS–(BUSINESS WIRE)–#lasertechnology—On the occasion of the 39th European Association of Urology Congress EAU, Quanta System asserts itself as a World Power Laser Manufacturer by the side of Doctors unveiling a game-changer solution in stone treatment: Quanta Magneto Technology™ On the way to its 40th anniversary Quanta System remains steadfast in its mission: innovate to improve … [Read more…]

DHCS Kicks Off Mobile Dental Van Tour

Smile, California campaign encourages families to establish good oral health habits early and take advantage of Medi-Cal dental benefits. FRESNO, Calif.–(BUSINESS WIRE)–The California Department of Health Care Services (DHCS) today kicked off its second mobile dental van tour in Fresno. Through the Smile California campaign, DHCS delivers preventive dental services to children and youth, enhancing … [Read more…]